Ambiguity and professional accountability in physiotherapy practice. Acquired brain injury rehabilitation across health care levels
AuthorIrgens, Eirik Lind
Paper I: Irgens, E., Henriksen, N. & Moe, S. (2016). Acquired brain injury rehabilitation: dilemmas in neurological physiotherapy across healthcare settings. European Journal of Physiotherapy, 18(4), 202-209. Published version not available in Munin due to publisher’s restrictions. Published version available at https://doi.org/10.1080/21679169.2016.1181206. Accepted manuscript version available in Munin at https://hdl.handle.net/10037/10574.
Paper II: Irgens, E., Henriksen, N. & Moe, S. (2018). Variations in physiotherapy practice in neurological rehabilitation trajectories – an explorative interview and observational study. Physiotherapy Theory and Practice. Published version not available in Munin due to publisher’s restrictions. Published version available at https://doi.org/10.1080/09593985.2018.1480679. MUNIN AAM
Paper III: Irgens, E., Henriksen, N. & Moe, S. (2018). Communicating information and professional knowledge in acquired brain injury rehabilitation trajectories – a qualitative study of physiotherapy practice. Disability and Rehabilitation. Published version not available in Munin due to publisher’s restrictions. Published version available at https://doi.org/10.1080/09638288.2018.1544295.
PublisherUiT The Arctic University of Norway
UiT Norges arktiske universitet
The following license file are associated with this item:
Showing items related by title, author, creator and subject.
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis Norum, Jan; Antonsen, Margaret Aarag; Tollåli, Geir; Al-Shibli, Khalid; Andersen, Gry; Svanqvist, Kristin-Helene; Helbekkmo, Nina (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-07-29)1 Norum J, et al . ESMO Open 2017; 2 :e000222. doi:10.1136/esmoopen-2017-000222 Open Access Abstr A ct Background P embrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. This drug has a high cost, and the cost- effectiveness ratio has been debated. Patients ...
The Use of eHealth and Provider-Based Health Services by Patients with Diabetes Mellitus: Protocol for a Cross-Sectional Study Hansen, Anne Helen; Bradway, Meghan; Brož, Jan; Claudi, Tor; Henriksen, Øystein; Wangberg, Silje C; Årsand, Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-10-31)<b>Background:</b> The prevalence of diabetes and the use of electronic health (eHealth) resources are increasing. People with diabetes need frequent monitoring and follow-up of health parameters, and eHealth services can be of great significance in this regard. However, little is known about the extent to which different kinds of eHealth tools are used, and how the use of eHealth is associated ...
Cochrane Collaboration Systematic Reviews may be based on trials not approved by a research ethics committee Jokstad, Asbjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-10-27)Systematic reviews (SR) may potentially contain reports of primary trials with ethical problems. The Cochrane Collaboration SRs are considered as the highest standard in evidence-based health care resources. All SRs completed during the last 5 years (2013–2017) under the management of the Oral Health Group of the Cochrane Collaboration were identified. All primary trials included in the Oral Health ...